| Name | Title | Contact Details |
|---|---|---|
Ed Amat |
Chief Growth Officer | Profile |
Maureen Marchek |
Chief Financial Officer | Profile |
Christie Knittel |
Chief People Officer | Profile |
Christie Knittel Mabry |
Chief People Officer | Profile |
Nathan Speicher |
Chief Financial Officer | Profile |
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
GenWay Biotech is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.